Behavioral effects of current Alzheimer's disease treatments: A descriptive review

Alzheimer's and Dementia

Volumn 4, Issue 1, 2008, Pages 49-60

  Cummings, Jeffrey L ^a   Mackell, Joan ^b   Kaufer, Daniel ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Behavior; Cholinesterase inhibitors; Memantine; Neuropsychiatric Inventory

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; RIVASTIGMINE; TACRINE;

AGITATION; ALZHEIMER DISEASE; APATHY; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BIOSIS; CLINICAL TRIAL; CORRELATION ANALYSIS; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG WITHDRAWAL; EMBASE; HUMAN; INFORMATION RETRIEVAL; INSTITUTIONALIZATION; IRRITABILITY; MEDLINE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MOOD CHANGE; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK REDUCTION; SCISEARCH; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; MENTAL DISORDERS;

EID: 38049023018     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.10.011     Document Type: Review

References (67)

1. Craig D., Mirakhur A., Hart D.J., McIlroy S.P., and Passmore A.P. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 13 (2005) 460-468
2. Cummings J.L. The neuropsychiatric burden of neurological diseases in the elderly. Int Psychogeriatr 17 (2005) 341-351
3. Hollingworth P., Hamshere M.L., Moskvina V., Dowzell K., Moore P.J., Foy C., et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc 54 (2006) 1348-1354
4. Lopez O.L., Becker J.T., Sweet R.A., Klunk W., Kaufer D.I., Saxton J., et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 15 (2003) 346-353
5. Piccininni M., Di Carlo A., Baldereschi M., Zaccara G., and Inzitari D. Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord 19 (2005) 276-281
6. Steffens D.C., Maytan M., Helms M.J., and Plassman B.L. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimer's Dis Other Demen 20 (2005) 367-373
7. Suh G.H., and Kim S.K. Behavioral and Psychological Signs and Symptoms of Dementia (BPSD) in antipsychotic-naive Alzheimer's disease patients. Int Psychogeriatr 16 (2004) 337-350
8. Black W., and Almeida O.P. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Psychogeriatr 16 (2004) 295-315
9. Rymer S., Salloway S., Norton L., Malloy P., Correia S., and Monast D. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 16 (2002) 248-253
10. Murman D.L., Chen Q., Powell M.C., Kuo S.B., Bradley C.J., and Colenda C.C. The incremental direct costs associated with behavioral symptoms in AD. Neurology 59 (2002) 1721-1729
11. Beeri M.S., Werner P., Davidson M., and Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 17 (2002) 403-408
12. Phillips V.L., and Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc 51 (2003) 188-193
13. Yaffe K., Fox P., Newcomer R., Sands L., Lindquist K., Dane K., et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. J Am Med Assoc 287 (2002) 2090-2097
14. Shin I.S., Carter M., Masterman D., Fairbanks L., and Cummings J.L. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry 13 (2005) 469-474
15. Conwell Y., Pearson J., and DeRenzo E.G. Indirect self-destructive behavior among elderly patients in nursing homes: a research agenda. Am J Geriatr Psychiatry 4 (1996) 152-163
16. Boustani M., Zimmerman S., Williams C.S., Gruber-Baldini A.L., Watson L., Reed P.S., et al. Characteristics associated with behavioral symptoms related to dementia in long-term care residents. Gerontologist 45 (2005) 56-61
17. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Moller H.-J., et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999) 237-244
18. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., and Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
19. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
20. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., and Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 50 (1998) 136-145
21. Seltzer B., Zolnouni P., Nunez M., Goldman R., Kumar D., Ieni J., et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 61 (2004) 1852-1856
22. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
23. Winblad B., Kilander L., Eriksson S., Minthon L., Batsman S., Wetterholm A.L., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
24. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006) 704-715
25. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
26. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., and Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology 54 (2000) 2269-2276
27. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 157 (2000) 4-15
28. Cummings J.L., McRae T., and Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14 (2006) 605-612
29. Gauthier S., Feldman H., Hecker J., Vellas B., Emir B., and Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 18 (2002) 347-354
30. Holmes C., Wilkinson D., Dean C., Vethanayagam S., Olivieri S., Langley A., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63 (2004) 214-219
31. Mega M.S., Masterman D.M., O'Connor S.M., Barclay T.R., and Cummings J.L. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56 (1999) 1388-1393
32. Wynn Z.J., and Cummings J.L. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 17 (2004) 100-108
33. Cummings J.L., Schneider E., Tariot P.N., and Graham S.M. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67 (2006) 57-63
34. Cummings J.L., Schneider L., Tariot P.N., Kershaw P.R., and Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 161 (2004) 532-538
35. Cummings J.L., Koumaras B., Chen M., and Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 3 (2005) 137-148
36. Aupperle P.M., Koumaras B., Chen M., Rabinowicz A., and Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 20 (2004) 1605-1612
37. Hatoum H.T., Lin S.J., Arcona S., Thomas S.K., Koumaras B., and Mirski D. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease. J Am Med Dir Assoc 6 (2005) 238-245
38. Feldman H., Gauthier S., Hecker J., Vellas B., Xu Y., Ieni J.R., et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 20 (2005) 559-569
39. Tariot P.N., Cummings J.L., Katz I.R., Mintzer J., Perdomo C.A., Schwam E.M., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
40. Johannsen P., Salmon E., Hampel H., Xu Y., Richardson S., Qvitzau S., et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 20 (2006) 311-325
41. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004) 2105-2115
42. Rockwood K., Mintzer J., Truyen L., Wessel T., and Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 71 (2001) 589-595
43. Brodaty H., Corey-Bloom J., Potocnik F.C., Truyen L., Gold M., and Damaraju C.R. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20 (2005) 120-132
44. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 291 (2004) 317-324
45. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
46. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
47. Gauthier S., Wirth Y., and Mobius H.J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20 (2005) 459-464
48. Matthews H.P., Korbey J., Wilkinson D.G., and Rowden J. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 15 (2000) 713-720
49. Tanaka M., Namiki C., Thuy D.H., Yoshida H., Kawasaki K., Hashikawa K., et al. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J Neurol Sci 225 (2004) 135-141
50. Paleacu D., Mazeh D., Mirecki I., Even M., and Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 25 (2002) 313-317
51. Barak Y., Bodner E., Zemishlani H., Mirecki I., and Aizenberg D. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr 33 (2001) 237-241
52. Weiner M.F., Martin-Cook K., Foster B.M., Saine K., Fontaine C.S., and Svetlik D.A. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry 61 (2000) 487-492
53. Patterson C.E., Passmore A.P., and Crawford V.L. A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. Int J Clin Pract 58 (2004) 144-148
54. Monsch A.U., and Giannakopoulos P. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Curr Med Res Opin 20 (2004) 931-938
55. Brodaty H., Woodward M., Boundy K., Barnes N., and Allen G. A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs 20 (2006) 935-943
56. Dantoine T., Auriacombe S., Sarazin M., Becker H., Pere J.J., and Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 60 (2006) 110-118
57. Frankfort S.V., Appels B.A., De Boer A., Tulner L.R., Van Campen J.P., Koks C.H., et al. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. Int J Clin Pract 60 (2006) 646-654
58. Gauthier S., Juby A., Morelli L., Rehel B., and Schecter R. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin 22 (2006) 2251-2265
59. Dautzenberg P.L., Wouters C.J., and Bootsma J.E. Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD. Int Psychogeriatr 18 (2006) 179-181
60. Bullock R., Touchon J., Bergman H., Gambina G., He Y., Rapatz G., et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21 (2005) 1317-1327
61. Wood S., Cummings J.L., Hsu M.-A., Barclay T., Wheatley M.V., Yarema K.T., et al. The use of the Neuropsychiatric Inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry 8 (2000) 75-83
62. Winblad B., and Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14 (1999) 135-146
63. Hope T., Keene J., Fairburn C., McShane R., and Jacoby R. Behaviour changes in dementia. 2: are there behavioural syndromes?. Int J Geriatr Psychiatry 12 (1997) 1074-1078
64. Lyketsos C.G., Breitner J.C., and Rabins P.V. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. Int J Geriatr Psychiatry 16 (2001) 1037-1042
65. Lyketsos C.G., Sheppard J.M., Steinberg M., Tschanz J.A., Norton M.C., Steffens D.C., et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 16 (2001) 1043-1053
66. Robert P.H., Verhey F.R., Byrne E.J., Hurt C., De Deyn P.P., Nobili F., et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects-consensus paper of the European Alzheimer disease consortium. Eur Psychiatry 20 (2005) 490-496
67. Kaufer D.I., Cummings J.L., and Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 9 (1996) 1-6